#1 Clinical Trials Search in Europe

Threonine

This article provides an overview of clinical trials investigating the use of threonine, an essential amino acid, in treating different medical conditions. These trials aim to evaluate the safety and efficacy of threonine-containing medications in patients with pulmonary arterial hypertension, short bowel syndrome, and other disorders. The studies explore various formulations and combinations of threonine with other substances to optimize treatment outcomes.

Table of Contents

What is Apraglutide?

Apraglutide is a novel medication being developed for the treatment of short bowel syndrome and other conditions. It is a synthetic peptide analogue of glucagon-like peptide-2 (GLP-2), consisting of 33 amino acids[1]. Apraglutide works by mimicking the effects of GLP-2, a naturally occurring hormone in the body that plays a role in intestinal growth and function.

Short Bowel Syndrome

Short bowel syndrome (SBS) is a condition that occurs when a large portion of the small intestine is missing or has been surgically removed. This results in reduced ability to absorb nutrients and fluids from food, often leading to malnutrition, dehydration, and other complications[1]. Patients with SBS often require parenteral support (PS), which means receiving nutrition through intravenous infusions.

Clinical Trials

Apraglutide is currently being studied in several clinical trials for the treatment of short bowel syndrome and other conditions:

  • A long-term safety study (STARS extend) is evaluating the safety and efficacy of apraglutide in patients with SBS who require parenteral support[1].
  • Another trial is investigating the use of apraglutide in patients with steroid-resistant gastrointestinal acute graft-versus-host disease (SR GI-aGVHD), a serious complication that can occur after stem cell transplantation[2].

Potential Benefits

The clinical trials are evaluating several potential benefits of apraglutide for patients with short bowel syndrome, including:

  • Reduction in the volume and frequency of parenteral support needed[1]
  • Improved nutritional status and body weight[1]
  • Enhanced quality of life, as measured by various patient-reported outcome scales[1]
  • Potential for some patients to achieve enteral autonomy (ability to maintain nutrition without parenteral support)[1]

Safety and Side Effects

The ongoing clinical trials are closely monitoring the safety of apraglutide. Some potential side effects and areas of concern being evaluated include:

  • Injection site reactions
  • Gastrointestinal obstructions
  • Gallbladder, biliary, and pancreatic issues
  • Fluid overload
  • Development of colorectal polyps
  • Risk of malignancies

It’s important to note that the full safety profile of apraglutide is still being established through these clinical trials[1].

Other Potential Uses

In addition to short bowel syndrome, apraglutide is being investigated for other potential uses:

  • Acute Graft-Versus-Host Disease (aGVHD): A clinical trial is evaluating the safety and efficacy of apraglutide in patients with steroid-resistant gastrointestinal acute graft-versus-host disease. This condition can occur after stem cell transplantation and affects the digestive system[2].

Conclusion

Apraglutide represents a promising new treatment option for patients with short bowel syndrome and potentially other conditions affecting the gastrointestinal system. While the results of ongoing clinical trials are still pending, this medication has the potential to significantly improve the quality of life for patients who currently rely on parenteral nutrition. As with any new medication, it’s important for patients to discuss the potential benefits and risks with their healthcare providers and to stay informed about the latest research developments.

Aspect Details
Medical Conditions Studied Pulmonary Arterial Hypertension, Short Bowel Syndrome, Acute Graft Versus Host Disease, Post-surgical Nutrition
Drug Formulations Solutions for injection, Emulsions for infusion, Peptide analogues
Administration Routes Intravenous infusion, Subcutaneous injection
Primary Objectives Safety assessment, Efficacy evaluation, Quality of life improvement, Optimal dosing determination
Key Endpoints Changes in disease-specific markers, Adverse event monitoring, Patient-reported outcomes, Survival rates
Trial Durations Ranging from several weeks to over 4 years for long-term studies
Patient Populations Adults (some trials include adolescents), Varying disease severities, Post-transplant patients
Safety Monitoring Adverse events, Laboratory tests, Vital signs, ECG measurements, Specific complications (e.g., GI obstructions, malignancies)

FAQ

  • What medical conditions are being studied in these clinical trials using threonine? The clinical trials are investigating the use of threonine-containing medications for various conditions, including pulmonary arterial hypertension, short bowel syndrome, gastrointestinal acute graft versus host disease, and nutritional support after major abdominal surgery.
  • How is threonine administered in these clinical trials? Threonine is administered in different forms depending on the trial. It may be given as part of a solution for injection, an emulsion for infusion, or as a component of a peptide analogue. The routes of administration include intravenous infusion and subcutaneous injection.
  • What are some of the primary objectives of these clinical trials? The primary objectives vary by trial but generally include assessing the safety and efficacy of threonine-containing treatments, evaluating their effects on specific disease markers, measuring changes in quality of life, and determining optimal dosing regimens.
  • Are there any specific side effects being monitored in these trials? Yes, the trials are monitoring for various side effects, including injection site reactions, gastrointestinal obstructions, gallbladder and pancreatic issues, fluid overload, and the development of colorectal polyps or new malignancies. Changes in vital signs, ECG measurements, and laboratory values are also being closely observed.
  • How long do these clinical trials typically last? The duration of the trials varies widely. Some studies last for a few weeks or months, while others, particularly those evaluating long-term safety and efficacy, can extend up to 208 weeks (4 years) or more.

Ongoing Clinical Trials on Threonine

  • Study of Intradialytic Parenteral Nutrition for Muscle Protein Production in Patients on Long-term Hemodialysis Treatment

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Nutrition Methods and Muscle Loss After Esophagectomy Using SmofKabiven and Drug Combination for Patients Recovering from Esophageal Surgery

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Early vs. Delayed Supplementary Parenteral Nutrition with SmofKabiven for Patients After Major Emergency Abdominal Surgery

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Pulmonary Arterial Hypertension (PAH): A type of high blood pressure that affects the arteries in the lungs and the right side of the heart, making it harder for the heart to pump blood through the lungs.
  • Short Bowel Syndrome (SBS): A condition where the body cannot absorb enough nutrients from food due to a lack of functional small intestine, often resulting from surgical removal of a portion of the small intestine.
  • Acute Graft Versus Host Disease (aGVHD): A complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's tissues.
  • Parenteral Nutrition: A method of feeding that bypasses the gastrointestinal tract and provides nutrients directly into the blood through a vein.
  • Apraglutide: A novel synthetic peptide analogue of glucagon-like peptide-2 (GLP-2) being studied for its potential benefits in treating short bowel syndrome and other conditions.
  • Enteral Autonomy: The ability of a patient to maintain adequate nutrition through oral or tube feeding without the need for parenteral nutrition.
  • MAGIC Score: Mount Sinai Acute GVHD International Consortium score, a system used to assess the severity of acute graft versus host disease.
  • Allogeneic Stem Cell Transplantation (alloSCT): A procedure where stem cells from a donor are transplanted into a recipient to treat various diseases, particularly blood and immune system disorders.
  • Steroid-Refractory (SR): A condition where the disease does not respond adequately to treatment with corticosteroids, requiring alternative therapies.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-apraglutide-for-patients-with-short-bowel-syndrome/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-apraglutide-for-patients-with-steroid-resistant-gastrointestinal-acute-graft-versus-host-disease/